AbbVie Inc. is reiterated as a Strong Buy ahead of Q3 earnings, with revenue growth expected to outpace the sector median.

Learn more about whether AbbVie Inc. or Avidity Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

One of the keys to a comfortable retirement is finding a steady and reliable stream of passive income. But Social Security ...

As markets adjust to higher rates and uneven growth, investors are gravitating towards businesses that balance resilience ...

Baron Health Care Fund gained for the quarter and outperformed its benchmark, the Russell 3000 Health Care Index. Read more ...

The U.S. Food and Drug Administration is reviewing a new Parkinson's disease drug called tavapadon that could give people ...

Market OverviewThe Global Anti-Aging Market is projected to grow at a CAGR of approximately 5–6% by 2029. The market’s growth is driven by a rising aging population, rapid technological advancements ...

Piramal Pharma Solutions has joined forces with IntoCell to broaden its bioconjugates offering and support innovation in the ...

Functional vision improvements are reported, with optimal pupil size considerations for varying light conditions being ...

Meta Platforms, Inc. (NASDAQ: META) is one of the stocks on Jim Cramer’s radar recently. A caller’s top five holdings were ...

The fresh probe could result in tariffs or other trade actions in the coming months related to pharmaceutical products.